Universal Ibogaine (TSXV:IBO) ROCE % : -76.32% (As of Apr. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Universal Ibogaine ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Universal Ibogaine's annualized ROCE % for the quarter that ended in Apr. 2024 was -76.32%.

Universal Ibogaine ROCE % Historical Data

The historical data trend for Universal Ibogaine's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Ibogaine ROCE % Chart

Universal Ibogaine Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Jul22

Jul23

ROCE %

Get a 7-Day Free Trial

-27.99

-40.41

-101.99

-499.07

-65.44

Universal Ibogaine Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24
ROCE %	Get a 7-Day Free Trial															-36.24	-27.30	-24.34	-20.40	-76.32

Universal Ibogaine ROCE % Calculation

Universal Ibogaine's annualized ROCE % for the fiscal year that ended in Jul. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jul. 2023 )		(A: Jul. 2022 )		(A: Jul. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jul. 2023 )		(A: Jul. 2022 )		(A: Jul. 2023 )
	=	-2.237	/	( ( (6.318 - 2.195)	+	(5.502 - 2.788) )	/ 2 )
	=	-2.237	/	( (4.123	+	2.714)	/ 2 )
	=	-2.237	/	3.4185
	=	-65.44 %

Universal Ibogaine's ROCE % of for the quarter that ended in Apr. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Apr. 2024 )		(Q: Jan. 2024 )		(Q: Apr. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Apr. 2024 )		(Q: Jan. 2024 )		(Q: Apr. 2024 )
	=	-3.288	/	( ( (5.607 - 1.186)	+	(5.318 - 1.123) )	/ 2 )
	=	-3.288	/	( ( 4.421	+	4.195 )	/ 2 )
	=	-3.288	/	4.308
	=	-76.32 %

(1) Note: The EBIT data used here is four times the quarterly (Apr. 2024) EBIT data.

Universal Ibogaine (TSXV:IBO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Universal Ibogaine ROCE % Related Terms

Thank you for viewing the detailed overview of Universal Ibogaine's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Universal Ibogaine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (TSXV:IBO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IBOGF:USA JC4:Germany

Address

815 8th Avenue South West, Suite 600, Calgary, AB, CAN, T2P 3P2

Website

https://www.universalibogaine.com

Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.

Executives

Ian Rabb

Senior Officer

Universal Ibogaine Headlines

From GuruFocus

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value

By Marketwired • 09-16-2024